Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 3,389 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 3,389 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the sale, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. The trade was a 6.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Noah Goodman also recently made the following trade(s):

• On Thursday, June 25th, Noah Goodman sold 5,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $114.00, for a total value of $570,000.00.
• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.00, for a total value of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Trading Down 0.6%

KYMR stock opened at $113.51 on Friday. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05. The business’s 50 day simple moving average is $86.87 and its 200 day simple moving average is $82.91. The firm has a market capitalization of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter last year, the firm posted ($0.82) EPS. The company’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KYMR. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Bank of America boosted their price objective on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley reiterated an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Finally, BTIG Research restated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $121.41.

Institutional Trading of Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC lifted its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC grew its position in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics in the 4th quarter worth about $63,000. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the second quarter valued at about $73,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.